Literature DB >> 31680143

Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors.

Bhumsuk Keam1,2, Chang Kyung Kang1, Kang Il Jun1, Song Mi Moon3, Koung Jin Suh3, Dae-Won Lee1,2, Chan-Young Ock1,2, Miso Kim1,2, Yunhee Choi4, Yoojoo Lim1,2, Kyung-Hun Lee1,2, Se Hyun Kim3, Tae Min Kim1,2, Tae-Yong Kim1,2, Do-Youn Oh1,2, Dong-Wan Kim1,2, Seock-Ah Im1,2, Jong Seok Lee3, Eu Suk Kim3, Hong Bin Kim3, Nam-Joong Kim1, Yu Jung Kim3, Wan Beom Park1, Myoung-Don Oh1.   

Abstract

Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs; n = 46) or cytotoxic agents (n = 90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results support annual influenza vaccinations for cancer patients receiving ICIs. Clinical Trials Registration clinicaltrials.gov (NCT03590808).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immune checkpoint inhibitor; immune-related adverse event; immunogenicity; influenza; vaccination

Mesh：

Substances：

Year:  2020        PMID： 31680143     DOI： 10.1093/cid/ciz1092

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

2.  The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.

Authors:  Tawanda Chivese; Joshua T Matizanadzo; Omran A H Musa; George Hindy; Luis Furuya-Kanamori; Nazmul Islam; Rafal Al-Shebly; Rana Shalaby; Mohammad Habibullah; Talal A Al-Marwani; Rizeq F Hourani; Ahmed D Nawaz; Mohammad Z Haider; Mohamed M Emara; Farhan Cyprian; Suhail A R Doi
Journal:  Pathog Glob Health       Date:  2022-01-31       Impact factor: 3.735

3.  INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).

Authors:  Melissa Bersanelli; Diana Giannarelli; Ugo De Giorgi; Sandro Pignata; Massimo Di Maio; Alberto Clemente; Elena Verzoni; Raffaele Giusti; Marilena Di Napoli; Giuseppe Aprile; Paola Ermacora; Annamaria Catino; Vieri Scotti; Francesca Mazzoni; Pamela Francesca Guglielmini; Antonello Veccia; Marco Maruzzo; Ernesto Rossi; Francesco Grossi; Chiara Casadei; Corrado Ficorella; Vincenzo Montesarchio; Francesco Verderame; Mimma Rizzo; Giorgia Guaitoli; Lucia Fratino; Caterina Accettura; Manlio Mencoboni; Fable Zustovich; Cinzia Baldessari; Saverio Cinieri; Andrea Camerini; Letizia Laera; Mariella Sorarù; Paolo Andrea Zucali; Valentina Guadalupi; Francesco Leonardi; Marcello Tiseo; Michele Tognetto; Francesco Di Costanzo; Carmine Pinto; Giorgia Negrini; Antonio Russo; Maria R Migliorino; Marco Filetti; Sebastiano Buti
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 4.  On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.

Authors:  Thilo Gambichler; Judith Reuther; Christina H Scheel; Jürgen Christian Becker
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

5.  Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors.

Authors:  Antonios Valachis; Camilla Rosén; Anthoula Koliadi; Evangelos Digkas; Alice Gustavsson; Andreas Nearchou; Gustav J Ullenhag
Journal:  Oncoimmunology       Date:  2021-02-17       Impact factor: 8.110

6.  Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.

Authors:  June Young Chun; Kichun Kim; Min Kyeong Lee; Chang Kyung Kang; Youngil Koh; Dong-Yeop Shin; Junshik Hong; Pyoeng Gyun Choe; Nam Joong Kim; Sung-Soo Yoon; Wan Beom Park; Inho Kim; Myoung-Don Oh
Journal:  BMC Infect Dis       Date:  2021-01-26       Impact factor: 3.090

Review 7.  COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.

Authors:  Joyce K Hwang; Tian Zhang; Andrew Z Wang; Zihai Li
Journal:  J Hematol Oncol       Date:  2021-02-27       Impact factor: 17.388

8.  Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.

Authors:  Muhammad Bilal Abid
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 9.  Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities.

Authors:  Zeinab Mohseni Afshar; Arefeh Babazadeh; Alireza Janbakhsh; Feizollah Mansouri; Terence T Sio; Mark J M Sullman; Kristin Carson-Chahhoud; Rezvan Hosseinzadeh; Mohammad Barary; Soheil Ebrahimpour
Journal:  Rev Med Virol       Date:  2021-10-22       Impact factor: 11.043

Review 10.  Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients.

Authors:  Emanuela Romano; Steve Pascolo; Patrick Ott
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.